心通医疗-B(02160)：VITAFLOW LIBERTY® FLEX获国家药监局批准注册

智通财经

2024-12-17

智通财经APP讯，心通医疗-B(02160)发布公告，于2024年12月16日，集团自主研发的第三代经导管主动脉瓣植入术(TAVI)产品VitaFlow Liberty® Flex经导管主动脉瓣可回收可控弯输送系统(“VitaFlow Liberty® Flex”)获得中国国家药品监督管理局颁发的注册批准。

VitaFlow Liberty® Flex为VitaFlow Liberty®输送系统的升级款产品，可与集团已获批的主动脉瓣膜配合使用，其传承了VitaFlow Liberty®输送系统的所有优势，并创新性地增加了3D空间调弯功能。其独有的内管调弯技术可使瓣膜在释放过程中保持同轴，植入更稳定精准，过弓以及跨瓣也更顺畅安全。同时 VitaFlow Liberty® Flex实现了瓣膜释放的交界对齐，保护冠脉通路，为未来冠脉介入预留空间。该产品为医生提供更优异的易用性体验，进一步提升手术效率和安全性，并减少手术并发症发生。此外，得益于公司产品全生命周期管理理念在研发阶段的深度实践，VitaFlow Liberty® Flex将有助于公司进一步降低生产成本。

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2492396932"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492396932\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2492396932?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2024-12-17 22:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492396932","market":"sh","top_or_hot":-1,"title":"心通医疗-B(02160)：VITAFLOW LIBERTY® FLEX获国家药监局批准注册","media":"智通财经","content":"<html><body><p>智通财经APP讯，<a href=\"https://laohu8.com/S/02160\">心通医疗-B</a>(02160)发布公告，于2024年12月16日，集团自主研发的第三代经导管主动脉瓣植入术(TAVI)产品VitaFlow Liberty® Flex经导管主动脉瓣可回收可控弯输送系统(“VitaFlow Liberty® Flex”)获得中国国家药品监督管理局颁发的注册批准。</p><p>VitaFlow Liberty® Flex为VitaFlow Liberty®输送系统的升级款产品，可与集团已获批的主动脉瓣膜配合使用，其传承了VitaFlow Liberty®输送系统的所有优势，并创新性地增加了3D空间调弯功能。其独有的内管调弯技术可使瓣膜在释放过程中保持同轴，植入更稳定精准，过弓以及跨瓣也更顺畅安全。同时 VitaFlow Liberty® Flex实现了瓣膜释放的交界对齐，保护冠脉通路，为未来冠脉介入预留空间。该产品为医生提供更优异的易用性体验，进一步提升手术效率和安全性，并减少手术并发症发生。此外，得益于公司产品全生命周期管理理念在研发阶段的深度实践，VitaFlow Liberty® Flex将有助于公司进一步降低生产成本。</p></body></html>","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>心通医疗-B(02160)：VITAFLOW LIBERTY® FLEX获国家药监局批准注册</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n心通医疗-B(02160)：VITAFLOW LIBERTY® FLEX获国家药监局批准注册\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-17 22:55 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1226243.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，心通医疗-B(02160)发布公告，于2024年12月16日，集团自主研发的第三代经导管主动脉瓣植入术(TAVI)产品VitaFlow Liberty® Flex经导管主动脉瓣可回收可控弯输送系统(“VitaFlow Liberty® Flex”)获得中国国家药品监督管理局颁发的注册批准。VitaFlow Liberty® Flex为VitaFlow Liberty®输送系统的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1226243.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0289961442.SGD","symbol_name":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1226243.html","article_id":"2492396932","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492396932","pubTimestamp":1734447355,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，心通医疗-B 发布公告，于2024年12月16日，集团自主研发的第三代经导管主动脉瓣植入术产品VitaFlow Liberty Flex经导管主动脉瓣可回收可控弯输送系统获得中国国家药品监督管理局颁发的注册批准。同时 VitaFlow Liberty Flex实现了瓣膜释放的交界对齐，保护冠脉通路，为未来冠脉介入预留空间。此外，得益于公司产品全生命周期管理理念在研发阶段的深度实践，VitaFlow Liberty Flex将有助于公司进一步降低生产成本。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU0069063385.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (USD) ACC","LU0289739343.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (SGD) ACC","BK4588":"碎股","LU1303367103.USD":"摩根大通多经理另类基金 A (acc)","LU0963586101.USD":"ALLIANZ GLOBAL SMALL CAP EQUITY \"AT\" ACC","LU2098885051.SGD":"JPMorgan Funds - Multi-Manager Alternatives A (acc) SGD","BK4512":"苹果概念","LU0124676726.USD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (USD) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","FLEX":"伟创力国际","BK4145":"电子制造服务","LU0472753341.HKD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU0175139822.USD":"AB FCP I Global Equity Blend A USD","BK1100":"医疗保健设备","LU0057025933.USD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (USD) ACC","02160":"心通医疗-B","BK4585":"ETF&股票定投概念","LU0689626769.HKD":"AB SICAV I - SUSTAINABLE US THEMATIC PORTFOLIO \"A\" (HKD) ACC","LU0511384066.AUD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (AUDHDG) ACC","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","BK1574":"生物医药B类股","BK1583":"高瓴概念","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC"},"translate_title":"Xintong Medical-B (02160): VITAFLOW LIBERTY ® FLEX was approved for registration by the State Food and Drug Administration","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02160":1,"FLEX":1},"content_text":"智通财经APP讯，心通医疗-B(02160)发布公告，于2024年12月16日，集团自主研发的第三代经导管主动脉瓣植入术(TAVI)产品VitaFlow Liberty® Flex经导管主动脉瓣可回收可控弯输送系统(“VitaFlow Liberty® Flex”)获得中国国家药品监督管理局颁发的注册批准。VitaFlow Liberty® Flex为VitaFlow Liberty®输送系统的升级款产品，可与集团已获批的主动脉瓣膜配合使用，其传承了VitaFlow Liberty®输送系统的所有优势，并创新性地增加了3D空间调弯功能。其独有的内管调弯技术可使瓣膜在释放过程中保持同轴，植入更稳定精准，过弓以及跨瓣也更顺畅安全。同时 VitaFlow Liberty® Flex实现了瓣膜释放的交界对齐，保护冠脉通路，为未来冠脉介入预留空间。该产品为医生提供更优异的易用性体验，进一步提升手术效率和安全性，并减少手术并发症发生。此外，得益于公司产品全生命周期管理理念在研发阶段的深度实践，VitaFlow Liberty® Flex将有助于公司进一步降低生产成本。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}